Cytotoxic T cells are of central importance in the immune systems response to disease. They recognize defective cells by binding to peptides presented on the cell surface by MHC (major histocompatibility complex) class I molecules. Peptide binding to MHC molecules is th... View more
1. Nielsen, M., and M. Andreatta. 2016. NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets. Genome Med. 8: 1- 9.
2. Vita, R., J. A. Overton, J. A. Greenbaum, J. Ponomarenko, J. D. Clark, J. R. Cantrell, D. K. Wheeler, J. L. Gabbard, D. Hix, A. Sette, and B. Peters. 2015. The immune epitope database (IEDB) 3.0. Nucleic Acids Res 43: D405-12.
3. Nielsen, M., and M. Andreatta. 2017. NNAlign: a platform to construct and evaluate artificial neural network models of receptor-ligand interactions. Nucleic Acids Res. .
4. Andreatta, M., and M. Nielsen. 2015. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics .
5. Deres, K., T. N. Schumacher, K. H. Wiesmuller, S. Stevanovic, G. Greiner, G. Jung, and H. L. Ploegh. 1992. Preferred size of peptides that bind to H-2 Kb is sequence dependent. Eur J Immunol 22: 1603-8.
6. Trolle, T., C. P. McMurtrey, J. Sidney, W. Bardet, S. C. Osborn, T. Kaever, A. Sette, W. H. Hildebrand, M. Nielsen, and B. Peters. 2016. The Length Distribution of Class I-Restricted T Cell Epitopes Is Determined by Both Peptide Supply and MHC Allele-Specific Binding Preference. J Immunol 196: 1480-7.
7. Lundegaard, C., K. Lamberth, M. Harndahl, S. Buus, O. Lund, and M. Nielsen. 2008. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 36.
8. Nielsen, M., C. Lundegaard, T. Blicher, K. Lamberth, M. Harndahl, S. Justesen, G. Roder, B. Peters, A. Sette, O. Lund, and S. Buus. 2007. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS ONE 2: e796.
9. Kreiter, S., M. Vormehr, N. van de Roemer, M. Diken, M. Löwer, J. Diekmann, S. Boegel, B. Schrörs, F. Vascotto, J. C. Castle, A. D. Tadmor, S. P. Schoenberger, C. Huber, Ö. Türeci, and U. Sahin. 2015. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520: 692-696.
10. Gubin, M. M., M. N. Artyomov, E. R. Mardis, and R. D. Schreiber. 2015. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J. Clin. Invest. 125: 3413-3421.